{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Negative+Dose&page=19", "query": { "intervention": "Negative Dose", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 1153, "total_pages": 116, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Negative+Dose&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Negative+Dose&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T17:42:11.963Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02001974", "title": "Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Paclitaxel+Reparixin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dompé Farmaceutici S.p.A", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 33, "start_date": "2012-02-27", "completion_date": "2015-01-15", "has_results": true, "last_update_posted_date": "2021-09-27", "last_synced_at": "2026-10-20T17:42:11.963Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Fairway, Kansas • Ann Arbor, Michigan + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02001974" }, { "nct_id": "NCT00887536", "title": "A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NSABP Foundation Inc", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "18 Years to 70 Years · Female only" }, "enrollment_count": 1613, "start_date": "2009-05", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2022-04-20", "last_synced_at": "2026-10-20T17:42:11.963Z", "location_count": 522, "location_summary": "Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 372 more", "locations": [ { "city": "Bessemer", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00887536" }, { "nct_id": "NCT05245071", "title": "Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-squamous Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Tusamitamab ravtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2022-06-01", "completion_date": "2024-11-20", "has_results": true, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-10-20T17:42:11.963Z", "location_count": 2, "location_summary": "Buffalo, New York • El Paso, Texas", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "El Paso", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05245071" }, { "nct_id": "NCT04305236", "title": "Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasm", "Hormone Receptor Positive Breast Carcinoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1, "start_date": "2020-07-23", "completion_date": "2022-02-16", "has_results": true, "last_update_posted_date": "2023-06-06", "last_synced_at": "2026-10-20T17:42:11.963Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04305236" }, { "nct_id": "NCT00021255", "title": "Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Herceptin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "18 Years to 70 Years · Female only" }, "enrollment_count": 3222, "start_date": "2001-04", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-11-15", "last_synced_at": "2026-10-20T17:42:11.963Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00021255" }, { "nct_id": "NCT05487885", "title": "Anhedonia, Development, and Emotions: Phenotyping and Therapeutics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Depression", "Anhedonia" ], "interventions": [ { "name": "Continuous theta burst stimulation (cTBS)", "type": "DEVICE" }, { "name": "Positive Affect Training", "type": "BEHAVIORAL" }, { "name": "Ketamine Injectable Solution", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "BEHAVIORAL", "DRUG" ], "sponsor": "Erika Forbes", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "15 Years to 25 Years" }, "enrollment_count": 123, "start_date": "2022-07-22", "completion_date": "2025-06-01", "has_results": true, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-10-20T17:42:11.963Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05487885" }, { "nct_id": "NCT03197935", "title": "A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple-negative Breast Cancer" ], "interventions": [ { "name": "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 333, "start_date": "2017-07-24", "completion_date": "2022-09-28", "has_results": true, "last_update_posted_date": "2023-10-26", "last_synced_at": "2026-10-20T17:42:11.963Z", "location_count": 12, "location_summary": "Palo Alto, California • Norwalk, Connecticut • Carrollton, Georgia + 8 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Carrollton", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03197935" }, { "nct_id": "NCT02822196", "title": "Serratus Anterior Muscle Plane Block vsThoracic Paravertebral Block For Unilateral Mastectomies", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Breast Cancer", "Mastectomy", "Regional Anesthesia", "Post Operative Pain" ], "interventions": [ { "name": "Lidocaine", "type": "DRUG" }, { "name": "Bupivacaine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 0, "start_date": "2018-12", "completion_date": "2019-12", "has_results": false, "last_update_posted_date": "2020-09-16", "last_synced_at": "2026-10-20T17:42:11.963Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02822196" }, { "nct_id": "NCT02566889", "title": "An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Inflammatory Bowel Diseases" ], "interventions": [ { "name": "Infliximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "6 Years to 16 Years" }, "enrollment_count": 53, "start_date": "2016-04", "completion_date": "2019-07", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-10-20T17:42:11.963Z", "location_count": 29, "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT02566889" }, { "nct_id": "NCT03611881", "title": "Assessing the Integration of Tobacco Cessation Treatment Into Lung Cancer Screening (LCS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Smoking, Tobacco" ], "interventions": [ { "name": "Counseling", "type": "BEHAVIORAL" }, { "name": "Nicotine patch", "type": "DRUG" }, { "name": "Community Resource", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 642, "start_date": "2019-04-01", "completion_date": "2024-01-31", "has_results": true, "last_update_posted_date": "2024-10-28", "last_synced_at": "2026-10-20T17:42:11.963Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Newton, Massachusetts • Oak Bluffs, Massachusetts + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Newton", "state": "Massachusetts" }, { "city": "Oak Bluffs", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03611881" } ] }